{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:24:58Z","timestamp":1761171898143,"version":"build-2065373602"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Several biologic agents have emerged as novel therapeutic options for patients with generalized myasthenia gravis (gMG); however, no clinical studies have yet explored the efficacy and safety of sequential biologic therapy in gMG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This multicenter, open-label, randomized controlled, exploratory clinical trial plans to enroll 60 patients with acetylcholine receptor antibody-positive gMG, randomized in a 1:1:1 ratio to receive one of the following treatment regimens: (1) E\u00a0+\u00a01w+T: efgartigimod 10 mg\/kg weekly for 4 weeks, followed by telitacicept 240 mg weekly starting 1 week after the last efgartigimod dose, continued for 25 weeks; (2) E\u00a0+\u00a02w+T: efgartigimod as above, followed by telitacicept 240 mg weekly starting 2 weeks after the last efgartigimod dose, continued for 24 weeks; or (3) T only: telitacicept monotherapy for 30 weeks. The primary endpoint is the change in the Quantitative Myasthenia Gravis (QMG) score from baseline to week 30. Secondary endpoints include changes in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline, proportion of patients achieving minimal manifestation status (MMS), changes in dosages of corticosteroid and other immunosuppressant, rates of MG relapse\/acute exacerbation and MG crisis, and safety outcomes. The pharmacokinetics\/pharmacodynamics (PK\/PD) of telitacicept will also be assessed. Recruitment is currently ongoing, but no participants have been enrolled as of yet.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study has been approved by the Ethics Committee in Clinical Research of the First Affiliated Hospital of Wenzhou Medical University. Results of the study will be disseminated to the relevant scientific, clinical and patient communities on trial closure.<\/jats:p>\n                    <jats:p>Trial registration number: The study was registered at ClinicalTrials.gov (NCT06827587).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1604786","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:17:22Z","timestamp":1761106642000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy, safety, and pharmacokinetics\/pharmacodynamics of telitacicept following efgartigimod in generalized myasthenia gravis: protocol of a randomized controlled trial"],"prefix":"10.3389","volume":"16","author":[{"given":"Jia","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feiteng","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingbing","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyun","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheyu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengli","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16180","article-title":"Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy","volume":"31","author":"Sacc\u00e0","year":"2024","journal-title":"Eur J Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1159\/000539577","article-title":"Prevalence, incidence, and mortality of myasthenia gravis and myasthenic syndromes: A systematic review","volume":"59","author":"Sciancalepore","year":"2025","journal-title":"Neuroepidemiology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"100063","DOI":"10.1016\/j.lanwpc.2020.100063","article-title":"Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study","volume":"5","author":"Chen","year":"2020","journal-title":"Lancet Reg Health West Pac"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1280226","article-title":"Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2021.1952982","article-title":"Emerging drugs for the treatment of myasthenia gravis","volume":"26","author":"Menon","year":"2021","journal-title":"Expert Opin Emerg Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"577424","DOI":"10.1016\/j.jneuroim.2020.577424","article-title":"Severe worsening of myasthenic symptoms after the eculizumab discontinuation","volume":"349","author":"Uzawa","year":"2020","journal-title":"J Neuroimmunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52142","article-title":"Efgartigimod for generalized myasthenia gravis: A multicenter real-world cohort study in China","volume":"11","author":"Luo","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50692","article-title":"Exacerbation of thymoma-associated myasthenia gravis following efgartigimod treatment related to anti-acetylcholine receptor antibody overshoot: A report of two cases","volume":"15","author":"Kawama","year":"2023","journal-title":"Cureus"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-01000-z","article-title":"Efgartigimod alfa in generalised myasthenia gravis: A profile of its use","volume":"37","author":"Heo","year":"2023","journal-title":"CNS Drugs"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16322","article-title":"A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis","volume":"31","author":"Yin","year":"2024","journal-title":"Eur J Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"17562864241251476","DOI":"10.1177\/17562864241251476","article-title":"Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study","volume":"17","author":"Lin","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07460-5","article-title":"Efgartigimod as a novel FcRn inhibitor for autoimmune disease","volume":"45","author":"Yang","year":"2024","journal-title":"Neurol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S513986","article-title":"Efgartigimod followed by telitacicept in adult generalized myasthenia gravis: A retrospective case series","volume":"18","author":"Zhang","year":"2025","journal-title":"J Inflammation Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","article-title":"Myasthenia gravis: the changing treatment landscape in the era of molecular therapies","volume":"20","author":"Iorio","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05077-6","article-title":"Benefit and danger from immunotherapy in myasthenia gravis","volume":"42","author":"Rodolico","year":"2021","journal-title":"Neurol Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02101-9","article-title":"Efgartigimod: A review in generalised myasthenia gravis","volume":"84","author":"Blair","year":"2024","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1501500","article-title":"Successful treatment of generalized myasthenia gravis with telitacicept: a Chinese case series and literature review","volume":"16","author":"Song","year":"2025","journal-title":"Front Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1549034","article-title":"Telitacicept as an alternative to non-steroidal immunosuppressive therapies in the treatment of myasthenia gravis: a study on clinical efficacy and steroid-sparing effect","volume":"16","author":"Fang","year":"2025","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1604786\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:17:23Z","timestamp":1761106643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1604786\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2025.1604786"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1604786","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"article-number":"1604786"}}